Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;208(3):491-499.
doi: 10.1007/s10549-024-07440-5. Epub 2024 Aug 4.

Oral minoxidil for late alopecia in cancer survivors

Alyce Mei-Shiuan Kuo  1 , Rachel E Reingold  1 , Kwami F Ketosugbo  1 , Alexander Pan  1 , Lukas Kraehenbuehl  1   2 , Stephen Dusza  1 , Devika Gajria  3 , Diana E Lake  3 , Jacqueline F Bromberg  3 , Tiffany A Traina  3 , Monica N Fornier  3 , Ayca Gucalp  3 , Brian M D'Alessandro  4 , Veronica Rotemberg  1 , Megan Dauscher  1 , Jerry Shapiro  5 , Shari B Goldfarb  3 , Alina Markova  1 , Mario E Lacouture  6   7   8
Affiliations

Oral minoxidil for late alopecia in cancer survivors

Alyce Mei-Shiuan Kuo et al. Breast Cancer Res Treat. 2024 Dec.

Abstract

Purpose: Late alopecia, defined as incomplete hair regrowth > 6 months following cytotoxic chemotherapy or > 6 months from initiation of endocrine therapy, negatively impacts quality of life and may affect dose intensity of adjuvant therapy. This study investigates the effect of oral minoxidil in women with chemotherapy and/or endocrine therapy-induced late alopecia.

Methods: The rate of clinical response was assessed by standardized photography and quantitated with trichoscopy.

Results: Two hundred and sixteen patients (mean age 57.8 ± 13.7) were included. The most common cancer diagnosis was breast, in 170 patients (79.1%). Alopecia developed after chemotherapy in 31 (14.4%) patients, endocrine monotherapy in 65 (30.1%) patients, and chemotherapy followed by endocrine therapy in 120 (55.6%) patients. In 119 patients, standardized photography assessments were used to determine clinical change in alopecia after a median of 105 (IQR = 70) days on oral minoxidil and revealed improvement in 88 (74%) patients. Forty-two patients received quantitative trichoscopic assessments at baseline and at follow-up after a median of 91 (IQR = 126) days on oral minoxidil. Patients had clinically and statistically significant increases in frontal hair shaft density (from 124.2 hairs/cm2 at initial to 153.2 hairs/cm2 at follow-up assessment, p = 0.008) and occipital shaft density (from 100.3 hairs/cm2 at initial to 123.5 hairs/cm2 at follow-up assessment. p = 0.004). No patients discontinued oral minoxidil due to adverse events.

Conclusions: Overall, oral minoxidil was well tolerated by patients and may benefit both frontal and occipital late alopecia in cancer survivors treated with cytotoxic and/or endocrine therapy by increasing hair shaft and follicle density.

Keywords: Adverse events; Alopecia; Breast cancer; Chemotherapy; Endocrine; Minoxidil.

PubMed Disclaimer

References

    1. Siegel RL, Miller KD, Fuchs HE, Jemal A (2022) Cancer statistics, 2022. CA Cancer J Clin 72(1):7–33. https://doi.org/10.3322/caac.21708 - DOI - PubMed
    1. Freites-Martinez A, Shapiro J, Goldfarb S et al (2019) Hair disorders in patients with cancer. J Am Acad Dermatol 80(5):1179–1196. https://doi.org/10.1016/j.jaad.2018.03.055 - DOI - PubMed
    1. Burstein HJ, Temin S, Anderson H et al (2014) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32(21):2255–2269. https://doi.org/10.1200/jco.2013.54.2258 - DOI - PubMed - PMC
    1. Freites-Martinez A, Shapiro J, van den Hurk C et al (2019) Hair disorders in cancer survivors. J Am Acad Dermatol 80(5):1199–1213. https://doi.org/10.1016/j.jaad.2018.03.056 - DOI - PubMed
    1. Saggar V, Wu S, Dickler MN, Lacouture ME (2013) Alopecia with endocrine therapies in patients with cancer. Oncologist 18(10):1126–1134. https://doi.org/10.1634/theoncologist.2013-0193 - DOI - PubMed - PMC

LinkOut - more resources